Category Archives: MS Treatment

Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), today announces the inclusion of the first patient in its Phase 2 trial of temelimab in MS at the Karolinska Institutets Academic Specialist Center (ASC), in Stockholm, Sweden. The one-year single center trial is planned to enrol 40 patients whose disability progresses without relapses, the key unmet medical need in multiple sclerosis, as patients disability builds-up over time despite the use of effective anti-inflammatory drugs. The study will assess safety, tolerability and efficacy measures based on the latest biomarkers associated with disease progression. Continue reading →

Her baby was coming, and her complications were growing more dangerous. But nowhere would take her an increasingly common story as Indias health care system buckles under pressure. NEW DELHI Neelam Kumari Gautam woke up at 5 a.m. Continue reading →

Rare, debilitating, but highly treatable, neuromyelitis optica syndrome disorders (mercifully better known by the acronym NMOSD) are a group of autoimmune conditions that mess with your central nervous system, the pathway by which your brain and the rest of your body send messages to each other. Continue reading →

ELON, N.C. Elon resident Mae Cousins is all smiles now thanks to some help from the Elon Police Department and American Lawn Care Continue reading →

NEW YORK, June 24, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer's disease. As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease Continue reading →

Officially, she calls herself Juliana, but she also goes by the name Anna Morena and has an organization of the same namethe Anna Foundation Uganda. Continue reading →

New York Citys the best marathon I think there is, she said. I ran Chicago, but it just didnt compare. Updated June 24, 2020 A commentary published this month on the website of the British Journal of Sports Medicine points out that covering your face during exercise comes with issues of potential breathing restriction and discomfort and requires balancing benefits versus possible adverse events Continue reading →

Aminat Lorsanova tried to run away from home five times before she finally made it. Away from the family she said had abused her physically and psychologically since she was a child. Away from Chechnya, where women like her are supposed not to exist Continue reading →

Read Time: Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals. Continue reading →

Researchers Present Case Studies on Teriflunomide Therapy in Patients with COVID-19, Multiple Sclerosis Our observations in these 5 patients suggest that teriflunomide may not need to be discontinued in patients with MS who develop an active COVID-19 infection, said corresponding author Rohit Bakshi, MD, in a statement.2 Teriflunomide is an immunomodulating drug commonly used to treat MS, which often requires long-term therapy. The drug modulates the immune response by selectively reducing the level of activated T and B lymphocytes without suppressing the full immune response.1 The ongoing international, multicenter study is examining 5 patients ranging in age from 52 to 79 years, all of whom have been taking teriflunomide for at least 5 months.1 All of the patients continued taking teriflunomide after their COVID-19 diagnosis and had self-limiting illness without experiencing a relapse of their MS.1 The authors posited that teriflunomide could prevent an excessive immune response while still maintaining enough defense against the virus. They also noted that patients with MS who were treated with teriflunomide generally also developed effective immunity to seasonal influenza and rabies after the vaccinations, which could be an important thing to note when looking to the future of a COVID-19 vaccine.1 The investigators did note that their case series was small, retrospective, open-label, uncontrolled, and non-randomized, so more studies are necessary in order to confirm and extend their preliminary findings.1 A delicate balance may be necessary in the host immune response to successfully confront COVID-19 infection, Bakshi said. Continue reading →